Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011

Pain Physician

Volumn 17, Issue 2, 2014, Pages

  Atluri, Sairam ^a   Sudarshan, Gururau ^b   Manchikanti, Laxmaiah ^c,d  

^a Tri State Spine Care Institute   (United States)

^b Cincinnati Pain Managment Consultants   (United States)

^c PAIN MANAGEMENT CENTER OF PADUCAH   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Abuse of opioids; Automation of reports and consolidated orders system (ARCOS); Drug abuse warning network (DAWN); Inappropriate use of opioids; International narcotics control board (INCB); Medical use of opioids; Opioid related fatalities

Indexed keywords

BUPRENORPHINE; CODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE;

ARTICLE; CANNABIS ADDICTION; COCAINE DEPENDENCE; DETOXIFICATION; DRUG MISUSE; DRUG MONITORING; DRUG USE; HEROIN DEPENDENCE; HUMAN; MEDICAL ASSESSMENT; REHABILITATION;

ANALGESICS, OPIOID; DATABASES, FACTUAL; HUMANS; OPIOID-RELATED DISORDERS; PAIN; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE DETECTION;

EID: 84897877492     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000; 283:1710-1714.
2. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004; 28:176-188.
3. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJE, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm II S, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I - Evidence assessment. Pain Physician 2012; 15:S1-S66.
4. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJE, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm II S, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 - Guidance. Pain Physician 2012; 15:S67-S116.
5. Manchikanti L, Boswell MV, Hirsch JA. Lessons learned in the abuse of painrelief medication: A focus on healthcare costs. Expert Rev Neurother 2013; 13:527-543.
6. Inocencio TJ, Carroll NV, Read EJ, Holdford DA. The economic burden of opioid- related poisoning in the United States. Pain Med 2013 [Epub ahead of print].
7. U.S. Food and Drug Administration News Release: FDA announces safety labeling changes and postmarket study requirements for extended-release and long-acting opioid analgesics. September 10, 2013. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367726.htm.
8. Manchikanti L, Helm II S, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV. Opioid epidemic in the United States. Pain Physician 2012; 15:ES9-ES38.
9. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic noncancer pain: an epidemiological study. Pain 2006; 125:172-179.
10. Federation of State Medical Boards of the US. Model guidelines for the use of controlled substances for the treatment of pain: A policy document of the Federation of State Medical Boards of the United States, Inc., Dallas, TX, 1998.
11. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Dono van MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C; American Pain Society- American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-130.
12. Phillips DM. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. JAMA 2000; 284:428-429.
13. McDonald DC, Carlson KE. Estimating the prevalence of opioid diversion by "doctor shoppers" in the United States. PLOS One 2013; 8:e69241.
14. Centers for Disease Control and Prevention. CDC grand rounds: Prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep 2012; 61:10-13.
15. Kuehn BM. Prescription drug abuse rises globally. JAMA 2007; 297:1306.
16. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013; 309:657-659.
17. US Government Accountability Office: Report to Congressional Requesters. Prescription Pain Reliever Abuse, December 2011. www.gao.gov/assets/590/587301.pdf.
18. Nelson LS, Perrone J. Curbing the opioid epidemic in the United States: The risk evaluation and mitigation strategy (REMS). JAMA 2012; 308:457-458.
19. Katz MH. Opioid prescriptions for chronic nonmalignant pain: Driving on a dangerous road. JAMA Intern Med 2013; 173:178.
20. Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011; 305:1346-1347.
21. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305,1315-1321.
22. Kuehn BM. Alarming nonfatal overdose rates found for opioids, sedatives, and tranquilizers. JAMA 2010; 303:2020-2021.
23. Wisniewski AM, Purdy CH, Blondell RD. The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits. J Addict Dis 2008; 27:1-11.
24. Federation of State Medical Boards. Model guidelines for the use of opioid analgesics in the treatment of chronic pain. July 2013. www.fsmb.org/pdf/pain_policy_july2013.pdf.
25. Centers for Disease Control and Prevention (CDC). Vital signs: Overdoses of prescription opioid pain relievers- United States, 1999-2008. MMWR Morb Mortal Wky Rep 2011; 60:1487-1492.
26. Physicians for Responsible Opioid Prescribing (PROP). www.supportprop.org
27. Report of the International Narcotics Control Board for 2011. United Nations, New York, NY, USA (2011). www.unodc.org/documents/southasia/reports/2011_INCB_ANNUAL_REPORT_english_PDF.pdf.
28. United Nations Office on Drugs and Crime. Ensuring availability of controlled medications for the relief of pain and preventing diversion and abuse: Striking the right balance to achieve the optimal public health outcome. Discussion paper based on a scientific workshop. UNODC, Vienna, Austria, January 18-19, 2011. www.unodc.org/docs/treatment/Pain/Ensuring_availability_of_controlled_medications_FINAL_15_March_CND_version.pdf.
29. Drug Abuse Warning Network. New DAWN: Why it cannot be compared with old DAWN. The New Dawn Report. September 2005. www.samhsa.gov/data/DAWN/DAWN%20-%20new%20vs%20old.pdf.
30. U.S. Department of Justice. Office of Diversion Control. Automation of Reports and Consolidated Orders System (ARCOS). www.deadiversion.usdoj.gov/arcos/.
31. Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network. www.samhsa.gov/data/dawn.aspx.
32. Freburger JK, Holmes GM, Agans RP, Jackman AM, Darter JD, Wallace AS, Castel LD, Kalsbeek WD, Carey TS. The rising prevalence of chronic low back pain. Arch Intern Med 2009; 169:251-258.
33. Hoy DG, Bain C, Williams G, March L, Brooks P, Blyth F, Woolf A, Vos T, Buchbinder R. A systematic review of the global prevalence of low back pain. Arthritis Rheum 2012; 64:2028-2037.
34. Hoy D, Brooks P, Blyth F, Buchbinder R. The epidemiology of low back pain. Best Pract Res Clin Rheumatol 2010; 24:769-781.
35. U.S. Social Security Administration. An-nual statistical report on the Social Security Disability Insurance Program, 2011. Release July 2012. www.ssa.gov/policy/docs/statcomps/di_asr/2011/di_asr11.pdf.
36. O'Connor NR. FDA boxed warnings: How to prescribe drugs safely. Am Fam Physician 2010; 81:298-303.
37. British Pain Society. Opioids for persistent pain: Good practice. A consensus statement prepared on behalf of the British Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Faculty of Addictions of the Royal College of Psychiatrists. London, UK, The British Pain Society, January 2010. www.britishpainsociety.org/book_opioid_main.pdf.
38. National Opioids Use Guideline Group (NOUGG). Canadian guidelines for safe and effective use of opioids for chronic non-cancer pain, Recommendations for Practice, Version 5.6. April 30, 2010. http://nationalpaincentre.mcmaster.ca/documents/opioid_guideline_part_b_v5_6.pdf
39. Agency Medical Directors Group. Interagency guidelines on opioid dosing for chronic non-cancer pain: An educational aid to improve care and safety with opioid therapy. 2010 Update. www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf.
40. Stein C, Reinecke H, Sorgatz H. Opioid use in chronic noncancer pain: Guidelines revisited. Curr Opin Anaesthesiol 2010; 23:598-601.
41. Reinecke H, Sorgatz H; German Society for the Study of Pain (DGSS). S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. Schmerz 2009; 23:440-447.
42. Hughes MA, Biggs JJ, Thiese MS, Graziano K, Robbins RB, Effiong AC. Recommended opioid prescribing practices for use in chronic non-malignant pain: A systematic review of treatment guidelines. J Manage Care Med 2011; 14:52-58.
43. Volkow ND, McLellan TA, Cotto JH, Karithanom M, Weiss SR. Characteristics of opioid prescriptions in 2009. JAMA 2011; 305:1299-1301.
44. McLellan AT. Treatment given high priority in new White House drug control policy. Interview by Bridget Kuehn. JAMA 2010; 303:821-822.
45. McLellan AT, Turner B. Prescription opioids, overdose deaths, and physician responsibility. JAMA 2008; 300:2672-2673.
46. Kuehn BM. Efforts aim to curb opioid deaths, injuries. JAMA 2009; 301:1213-1215.
47. Kuehn BM. Opioid prescriptions soar: Increase in legitimate use as well as abuse. JAMA 2007; 297:249-251.
48. Fauber J. MedPage Today/Milwaukee Journal Sentinel series triggers senate investigation. Medpage Today, May 9, 2012. www.medpagetoday.com/PainManagement/PainManagement/32582.
49. Meier B. Senate inquiry into painkiller makers' ties. New York Times, May 8, 2012. www.nytimes.com/2012/05/09/health/senate-panel-to-examinenarcotic-drug-makers-financial-ties.html?_r=0.
50. Ornstein C, Weber T. American Pain Foundation shuts down as senators launch investigation of prescription narcotics. ProPublic, May 8, 2012. www.propublica.org/article/senate-panel-investigates-drug-company-ties-to-paingroups.
51. Centers for Disease Control and Prevention. Prescription Drug Overdose: State Law. www.cdc.gov/HomeandRecreationalSafety/poisoning/laws/index.html.
52. Gudin JA. The changing landscape of opioid prescribing: Long-acting and extended-release opioid class-wide Risk Evaluation and Mitigation Strategy. Ther Clin Risk Manag 2012; 8:209-217.
53. Peppin JF, Coleman JJ, Kirsh KL. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management. Issues Law Med 2011; 27:91-119.
54. Manchikanti L, Hirsch JA. The pains of chronic opioid usage [Spotlight]. AHRQ WebM&M [serial online]. September 2013. http://webmm.ahrq.gov/case.aspx?caseID=305.
55. Mercadante S, Craig D, Giarratano A. US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioids: Pros and cons, and a European perspective. Drugs 2012; 72:2327-2332.
56. Stanos S. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids. Phys Sportsmed 2012; 40:12-20.
57. Juurlink DN, Dhalla IA, Nelson LS. Improving opioid prescribing: the New York City recommendations. JAMA 2013; 309:879-880.
58. Alford DP. Chronic back pain with possible prescription opioid misuse. JAMA 2013; 309(9):919-925.
59. Dowell D, Kunins HV, Farley TA. Opioid analgesics--risky drugs, not risky patients. JAMA 2013; 309:2219-2220.
60. Kuehn BM. FDA tightens indications for using long-acting and extended-release opioids to treat chronic pain. JAMA 2013; 310:1547-1548.
61. Kuehn BM. FDA committee: More restrictions needed on hydrocodone combination products. JAMA 2013; 309:862.
62. Kopelow M. Continuing education in opioid prescribing. JAMA 2012; 308:2081-2082.
63. Alexander GC, Kruszewski SP, Webster DW. Rethinking opioid prescribing to protect patient safety and public health. JAMA 2012; 308:1865-1866.
64. Kuehn BM. Petition targets painkiller marketing in effort to curb overdose deaths. JAMA 2012; 308:1194-1196.
65. Kuehn BM. Methadone overdose deaths rise with increased prescribing for pain. JAMA 2012; 308:749-750.
66. Kuehn BM. Scientists, officials eye tools aimed at combating abuse of painkillers. JAMA 2012; 307:19-21.
67. Manchikanti L, Cash KA, Malla Y, Pampati V, Fellows B. A prospective evaluation of psychotherapeutic and illicit drug use in patients presenting with chronic pain at the time of initial evaluation. Pain Physician 2013; 16:E1-E13.
68. Kentucky Board of Medical Licensure (KBML). Guidelines for the Use of Controlled Substances in Pain Treatment. http://media.kentucky.com/smedia/2008/08/01/19/UseofCSsinPainTreatment.source.prod_affiliate.79.pdf.
69. Fishman SM, Federation of State Medical Boards of the United States. Responsible Opioid Prescribing: A Clinician's Guide. (2nd Edition, Revised and Expanded). Washington, DC: Waterford Life Science; 2012.
70. Solanki DR, Koyyalagunta D, Shah RV, Silverman SM, Manchikanti L. Monitoring opioid adherence in chronic pain patients: Assessment of risk of substance misuse. Pain Physician 2011; 14:E119-E131.
71. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: A review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician 2012; 15:ES67-ES92.
72. Atluri S, Akbik H, Sudarshan G. Prevention of opioid abuse in chronic noncancer pain: an algorithmic, evidence based approach. Pain Physician 2012; 15:ES177-ES189.
73. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011; 12:747-754.
74. Betses M, Brennan T. Abusive prescribing of controlled substances - a pharmacy view. N Engl J Med 2013; 369:989-991.
75. Heins JR, Lambrechts E. Prescription drug monitoring programs. S D Med 2013; 66:191, 193.
76. Garcia AM. State laws regulating prescribing of controlled substances: Balancing the public health problems of chronic pain and prescription painkiller abuse and overdose. J Law Med Ethics 2013; 41:42-45.
77. Gugelmann H, Perrone J, Nelson L. Windmills and pill mills: Can PDMPs tilt the prescription drug epidemic? J Med Toxicol 2012; 8:378-386.
78. Chakravarthy B, Shah S, Lotfipour S. Prescription drug monitoring programs and other interventions to combat prescription opioid abuse. West J Emerg Med 2012; 13:422-425.
79. Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki D, Jordan AE, Colson J. Urine drug testing in chronic pain. Pain Physician 2011; 14:123-143.
80. Franklin GM, Mai J, Turner J, Sullivan M, Wickizer T, Fulton-Kehoe D. Bending the prescription opioid dosing and mortality curves: Impact of the Washington State opioid dosing guideline. Am J Ind Med 2012; 55:325-331.
81. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC. Association between opioid prescribing patterns and opioid overdoserelated deaths. JAMA 2011; 305:1315-1321.
82. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Overdose and prescribed opioids: Associations among chronic non-cancer pain patients. Ann Intern Med 2010; 152:85-92.
83. Braden JB, Russo J, Fan MY, Edlund MJ, Martin BC, DeVries A, Sullivan MD. Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med 2010; 170:1425-1432.
84. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med 2011; 5:e13-e22.
85. Swedlow A, Ireland J, Johnson G. Prescribing patterns of Schedule II opioids in California Workers' Compensation. Oakland, CA: California Workers' Compensation Institute, March 2011. www.cwci.org/document.php?file=1438.pdf.